Shattuck Labs, Inc (STTK)

Etorro trading 970x250
Shattuck Labs, Inc (STTK) Logo

About Shattuck Labs, Inc

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas. Address: 1018 West 11th Street, Austin, TX, United States, 78703

Shattuck Labs, Inc News and around…

Latest news about Shattuck Labs, Inc (STTK) common stock and company :

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
26 Nov, 2021 FinancialContent

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK
26 Nov, 2021 Yahoo! Finance

Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Investigation – STTK
25 Nov, 2021 Yahoo! Finance

NEW YORK, Nov. 25, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Shattuck Labs, Inc. (NASDAQ: STTK) resulting from allegations that Shattuck may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Shattuck securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
23 Nov, 2021 FinancialContent

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Shattuck Labs, Inc. (STTK) Investigation
22 Nov, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK).

EQUITY ALERT: Rosen Law Firm Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Investigation – STTK
22 Nov, 2021 FinancialContent

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Shattuck Labs, Inc. (NASDAQ: STTK) resulting from allegations that Shattuck may have issued materially misleading business information to the investing public.

Look Under The Hood: IWN Has 14% Upside
16 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $199.48 per unit.

75 Biggest Movers From Yesterday
10 Nov, 2021 FinancialContent

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check ...

Takeda, Shattuck Labs Terminate Immuno-Oncology Pact
09 Nov, 2021 FinancialContent

Shattuck Labs Inc(NASDAQ: STTK) andTakeda Pharmaceutical Co Ltd(NYSE: TAK) mutually agreed to terminate the ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
09 Nov, 2021 FinancialContent

Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The ...

58 Stocks Moving In Monday's Mid-Day Session
09 Nov, 2021 FinancialContent

Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire ...

Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252
09 Nov, 2021 Yahoo! Finance

– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients – – SL-172154 (SIRPα-Fc-CD40L) demonstrates high CD47 target occupancy and CD40 target engagement and evidence of dose-dependent immune activation in heavily pretreated platinum resistant ovarian cancer patients – – Open IND for clinical trial of SL-172154 in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-M

Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights
09 Nov, 2021 Yahoo! Finance

– Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials remain ongoing – – SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients – – SL-172154 (SIRPα-Fc-CD40L) demonstrates high levels of CD47 target occupancy and evidence of dose-dependent CD40-med

Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
04 Nov, 2021 Yahoo! Finance

– Event scheduled for Friday, November 12, 2021 at 8:00 a.m. ET – AUSTIN, TX and DURHAM, NC, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced it will host a live webcast presentation highlighting the clinical

Shattuck Labs Announces Participation in Upcoming November Investor Conferences
03 Nov, 2021 Yahoo! Finance

AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in four virtual investor conferences in November 2021. Presentation Details Conference: Ber

Shattuck Labs Announces Changes to its Board of Directors
28 Oct, 2021 Yahoo! Finance

Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D.; Dr. George Golumbeski, Ph.D., appointed as Chairman of the Board AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announc

What Type Of Shareholders Own The Most Number of Shattuck Labs, Inc. (NASDAQ:STTK) Shares?
12 Oct, 2021 Yahoo! Finance

Every investor in Shattuck Labs, Inc. ( NASDAQ:STTK ) should be aware of the most powerful shareholder groups...

Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
01 Oct, 2021 Yahoo! Finance

AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present four posters at SITC’s 36th Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021. Presentation Details Abstract Title: Phase 1 D

OMFS's Holdings Could Mean 20% Gain Potential
10 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.16 per unit.

Shattuck Labs Announces Participation in Upcoming September Conferences
01 Sep, 2021 FinancialContent
60 Biggest Movers From Yesterday
24 Aug, 2021 FinancialContent

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be ...

35 Stocks Moving In Monday's Mid-Day Session
23 Aug, 2021 FinancialContent

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by ...

Stocks That Hit 52-Week Lows On Friday
20 Aug, 2021 FinancialContent

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) ...

Stocks That Hit 52-Week Lows On Thursday
19 Aug, 2021 FinancialContent

Thursday morning, 173 companies reached new 52-week lows. Areas of Interest: The largest company by market ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Aug, 2021 FinancialContent

Gainers Xenetic Biosciences (NASDAQ:XBIO) shares rose 20.37% to $3.9 during Thursday's pre-market session. The ...

Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252
11 Aug, 2021 FinancialContent
Earnings Scheduled For August 11, 2021
11 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second ...

Shattuck Labs Announces Participation in the BTIG Biotechnology Conference
06 Aug, 2021 FinancialContent
How The Pieces Add Up: XBI Headed For $216
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $216.21 per unit.

Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021
04 Aug, 2021 FinancialContent

Shattuck Labs, Inc (STTK) is a NASDAQ Common Stock listed in ,

970x250